Dermatitis Research Today is a free monthly online journal that collates and summarizes the latest research about Dermatitis, including details on contact-, seborrheic-, atopic-, allergic-dermatitis, treatment.

Pleomorphic presentation of cutaneous lesions associated with the proteasome inhibitor bortezomib in patients with multiple myeloma.

Wu KL, Heule F, Lam K, Sonneveld P

Department of Hematology, Erasmus MC, Rotterdam, The Netherlands. k.wu@erasmusmc.nl

The clinical course and histologic findings of cutaneous adverse reactions associated with bortezomib treatment are presented in this study. Bortezomib (Velcade) is a proteasome inhibitor, which is used as a novel anticancer drug in the treatment of multiple myeloma. We have conducted an observational analysis of 47 patients with myeloma who were treated with bortezomib in 3 prospective clinical trials. Cutaneous adverse reactions were observed in 6 patients (13%). Five patients presented with sharply demarcated erythematous plaques or nodules on the trunk and one patient had generalized morbilliform erythema with ulcerations and fever. The time between the first bortezomib dose and occurrence of the cutaneous eruptions was at least 30 days. The cutaneous eruptions usually resolve within a few days. One patient withdrew from further treatment because of severe cutaneous toxicity. The histologic findings ranged from perivascular dermatitis to interstitial and interface dermatitis corresponding with clinically more extensive lesions.

Published 20 October 2006 in J Am Acad Dermatol, 55(5): 897-900.
Full-text of this article is available online (may require subscription).

© 2004-2008 Dermatitis Research Today. All Rights Reserved.